Asia-Pacific
In an exclusive interview, Rouse CEO Luke Minford, Arnold & Siedsma managing partner Steve Duxbury, and Wrays executive chairman Gary Cox discuss plans to build the world’s first ‘truly integrated’ global IP services business
Boasting four former Spruson & Ferguson leaders and with offices in Hong Kong and Singapore, the IP firm aims to provide fast, practical advice to clients
Catherine Lee, one of Managing IP’s Top 250 Women in IP 2025, discusses her ‘soft’ approach to leadership and why building a community at work is important
Youngmin Park joins us for our ‘Five minutes with’ series to discuss learning languages, moonlighting as a drummer, and why late is better than never
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins outline the IP changes that will come into force in 2023, and share their opinion on the merits and drawbacks of each -
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law summarises the key points of the Korean Intellectual Property Office’s updated guidance regarding artificial intelligence patent filings as the intellectual property world adapts to a growing area
-
Sponsored by FB RiceJacqueline Warner and Marcus Caulfield of FB Rice explain the significance of common general knowledge (CGK) in the patentability of inventions in Australia and the evidentiary processes that are adopted as a result
-
Sponsored by ABE & PartnersTakanori Abe of ABE & Partners examines the Tokyo District Court and Intellectual Property High Court rulings on Ricoh’s claim that Ds Japan infringed its patent rights regarding toner cartridges for printers
-
Sponsored by Saint Island International Patent & Law OfficesFrank Liu of Saint Island International Patent & Law Offices describes the progress of a significant patent infringement case in Taiwan and the extended involvement of the Intellectual Property and Commercial Court
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
